Stock · NSE
DRREDDY 1,208.00 ▲ 5.00 (0.42%) Last 2 days · 15m candles 9/10/2026, 02:01:01
Open: 1,195.10 High: 1,211.40 Low: 1,195.10 Prev: 1,203.00
VERIFIED ET Finance · 7h ★ ON YOUR LIST ☆
Dr Reddy’s Laboratories receives two observations for Andhra Pradesh facility AI summary · NEUTRAL
· Dr Reddy's Laboratories' FTO-11 manufacturing unit in Andhra Pradesh underwent a US health regulator inspection. · The Pre-Approval Inspection (PAI) took place from October 5-7. · The company received two observations following the inspection. VERIFIED Mint Markets · 16h ★ ON YOUR LIST ☆
Pharma stocks to buy ahead of Q2 results: Acutaas Chemicals, Mankind Pharma, Ipca Labs - Max upside? Target price AI summary · NEUTRAL
· Pharma exporters may benefit from rupee depreciation ahead of Q2 results. · Elevated freight and input costs pose potential risks for the sector. · InCred identifies potential pressure on Dr Reddy’s, Divi’s, Lupin, Cipla, Torrent Pharma, and Blue Jet Healthcare in Q2FY27. VERIFIED ET Stocks · 10d ★ ON YOUR LIST ☆
Market wrap: Infosys, Dr Reddy's Labs, Tata Motors PV, Power Grid top gainers and losers on Nifty and Sensex on Monday AI summary · NEGATIVE
· Indian equity markets closed significantly lower on Monday, with the Nifty down 1.56% and the Sensex down 1.52%. · PSU banks and realty stocks were the biggest decliners, while Dr Reddy’s Labs and Infosys were among the few gainers. · India VIX saw a substantial increase of 12.54%. Google News, NIFTY/SENSEX · 20d ★ ON YOUR LIST ☆
Dr. Reddy’s, BEML, Vedanta, Eternal among buzzing stocks as SENSEX jumps over 200 pts; NIFTY trades above 23,300 - upstox.com Summarize with AI → VERIFIED ET Finance · 20d ★ ON YOUR LIST ☆
QDENGA dengue vaccine to hit India market in 2027; Dr Reddy’s to sell it AI summary · NEUTRAL
· India's first approved dengue vaccine, QDENGA, will launch in the private market by mid-2027. · Dr Reddy's Laboratories will distribute and promote the vaccine for individuals aged four to sixty. · Takeda will retain rights for public market distribution as a future objective. VERIFIED ET Stocks · 22d ★ ON YOUR LIST ☆
JM Financial sees up to 28% upside in Dr Reddy’s and Aurobindo Pharma. Should you buy? AI summary · POSITIVE
· JM Financial maintained Buy ratings on Dr Reddy’s Laboratories and Aurobindo Pharma. · The brokerage anticipates up to 28% upside for both companies in the next 12 months. · JM Financial cited stronger earnings growth, business diversification, and new product launches as key drivers. VERIFIED Mint Markets · 26d ★ ON YOUR LIST ☆
Best stocks to Buy: Axis Bank, Dr Reddy’s Labs, Indus Towers - Sumeet Bagadia recommends for Tuesday | Target, stop-loss AI summary · NEUTRAL
· Sumeet Bagadia recommends three stocks to buy on Monday. · The recommended stocks are Axis Bank, Dr Reddy’s Labs, and Indus Towers. · Bagadia provides buying ranges, targets, and stop-loss levels for these stocks. VERIFIED Mint Companies · 45d ★ ON YOUR LIST ☆
After the lottery win: why Dr Reddy’s may be doing much more in its laboratories AI summary · NEUTRAL
· Dr Reddy's reported record profits driven by a copycat drug. · The company's co-chairman, G.V. Prasad, faces the challenge of sustaining growth without this drug. · Future growth may depend on biosimilars and innovation within the company's laboratories. VERIFIED Economic Times News · 47d ★ ON YOUR LIST ☆
HDFC Bank, Trent among 10 stocks that saw the biggest decrease in mutual fund value in July AI summary · NEGATIVE
· Ten stocks experienced the largest month-on-month decrease in mutual fund holdings during July. · HDFC Bank, Axis Bank, and L&T were among the top stocks with the biggest decline in mutual fund value. · Varun Beverages, Dr Reddy’s Labs, BOB, and Avenue Supermarts also saw significant reductions in mutual fund holdings. VERIFIED ET Finance · 55d ★ ON YOUR LIST ☆
Gland Pharma appoints Dr Reddy’s senior executive Deepak Sapra as CEO AI summary · NEUTRAL
· Gland Pharma has appointed Deepak Sapra as its new chief executive officer. · Sapra's tenure is set to begin on November 16, 2026, pending his acceptance. · He brings 27 years of executive experience, with over 23 years in pharmaceuticals, and currently leads API and Services at Dr Reddy’s Laboratories. VERIFIED ET Markets · 66d ★ ON YOUR LIST ☆
Nifty Q1 earnings grow 11% to beat estimate, says Motilal Oswal; picks Bharti Airtel, SBI, ICICI Bank among top bets AI summary · POSITIVE
· Nifty companies' Q1 profits grew 11% year-on-year, exceeding Motilal Oswal's 7% estimate. · Reliance Industries, JSW Steel, ICICI Bank, Bajaj Finance, and Axis Bank contributed 59% of the incremental earnings growth. · InterGlobe Aviation, ITC, Dr Reddy’s, Cipla, and Maruti Suzuki were among the companies that negatively impacted earnings growth. VERIFIED Economic Times News · 77d ★ ON YOUR LIST ☆
Dr Reddy’s shares crack 9% after weak Q1; these 3 brokerages slash their target prices AI summary · NEGATIVE
· Dr Reddy's shares fell 9% following a weak Q1 FY27 performance. · Net profit decreased by 69% year-on-year to Rs 443 crore, and revenue declined 6% to Rs 8,071 crore. · A Rs 240 crore semaglutide API-related impact and increased costs affected earnings. VERIFIED ET Markets · 77d ★ ON YOUR LIST ☆
Dr Reddy’s shares crash 9% after weak Q1 results. Here’s why these 3 brokerages are bearish AI summary · NEGATIVE
· Dr Reddy's shares fell 9% following weak Q1 FY27 results. · Net profit decreased by 69% year-on-year to Rs 443 crore. · Revenue declined 6% to Rs 8,071 crore, impacted by API provisions and increased costs. VERIFIED ET Finance · 78d ★ ON YOUR LIST ☆
Dr Reddy’s aims to resume semaglutide supply by November after API fix AI summary · NEUTRAL
· Dr Reddy's anticipates resuming semaglutide supplies by November following the resolution of quality issues. · The company has identified the root cause of the API problem and plans to implement corrective actions by September. · Dr Reddy's expects to supply millions of semaglutide units within the current fiscal year. VERIFIED Mint Companies · 78d ★ ON YOUR LIST ☆
Dr Reddy’s reports muted Q1FY27 results, net profit drops 69% AI summary · NEGATIVE
· Dr Reddy's reported Q1FY27 results that missed estimates. · Revenue for the quarter decreased by 5.6% to ₹8,071 crore. · Net profit saw a significant drop of 69% to ₹444 crore. VERIFIED ET Markets · 88d ★ ON YOUR LIST ☆
Stocks in news: DMart, HCL Tech, ICICI Pru AMC, Dr Reddy’s, NTPC, IndiGo AI summary · NEUTRAL
· DMart reported an 11.3% rise in net profit. · HCL Tech and ICICI Pru AMC will announce their first quarter results today. · IndiGo received a warning letter from DGCA. VERIFIED ET Stocks · 90d ★ ON YOUR LIST ☆
Dr. Reddy's Lab among 4 F&O stocks that saw a high increase in futures open interest AI summary · NEUTRAL
· Futures open interest increased by over 11% in nine NSE F&O stocks on July 9. · Dr. Reddy's, Lodha Developers, Mazagon Dock, and HDFC Life saw significant rises in futures open interest. · This rise in open interest indicates fresh participation from traders. Google News, NIFTY/SENSEX · 90d ★ ON YOUR LIST ☆
Stocks to Watch Today (July 10): TCS, Maruti Suzuki, JSW Steel, NALCO, SAIL, Federal Bank, Dr Reddy And More in Focus; Nifty & Sensex Expected To Open Higher - The Sunday Guardian Summarize with AI → VERIFIED ET Finance · 91d ★ ON YOUR LIST ☆
Dr Reddy’s pauses weight loss drug on quality fears AI summary · NEGATIVE
· Dr Reddy's Laboratories is pausing semaglutide injection supplies until at least October due to identified impurities. · The company has assured that existing market products are safe for patient use. · Torrent Pharmaceuticals and USV Ltd are recalling semaglutide batches sourced from Dr Reddy's. Google News, NIFTY/SENSEX · 91d ★ ON YOUR LIST ☆
Nifty reclaims 24,000; midcaps outshine as Dr. Reddy’s tanks 5%, pharma diverges - BusinessLine Summarize with AI → Google News, NIFTY/SENSEX · 101d ★ ON YOUR LIST ☆
Nifty Pharma Index Hits Fresh 52-Week High; Dr Reddy’s, Cipla, Ajanta Pharma Lead Rally on GLP-1 Opportunity - India Infoline Summarize with AI → Google News, NIFTY/SENSEX · 101d ★ ON YOUR LIST ☆
Sensex, Nifty trade flat; Dr Reddy’s tops gainers, Kotak Bank leads losses - BusinessLine Summarize with AI → VERIFIED ET Markets · 116d ★ ON YOUR LIST ☆
Stocks in news: Dr Reddy’s, Adani Green, KIMS, JSW Energy, Nestle India AI summary · POSITIVE
· Nifty defended the 23,000 support and reclaimed 23,500. · Dr Reddy’s, Adani Green, and JSW Energy are in focus due to corporate developments. · Markets saw a strong rebound on Friday driven by positive global cues and easing geopolitical tensions. Google News, SEBI · 133d ★ ON YOUR LIST ☆
Dr. Reddy’s (NYSE: RDY) reports full SEBI compliance for FY 2026 - Stock Titan Summarize with AI → VERIFIED ET Finance · 141d ★ ON YOUR LIST ☆
Dr Reddy’s launches oral semaglutide in India AI summary · NEUTRAL
· Dr Reddy’s Laboratories has launched its oral semaglutide biosimilar for type 2 diabetes in India, named Obeda. · Obeda is available in three tablet strengths for daily use. · Dr Reddy's is the second Indian company to introduce oral semaglutide domestically. VERIFIED ET Finance · 145d ★ ON YOUR LIST ☆
Dr Reddy’s launches generic Semaglutide injection, popular weight-loss drug, in Canada AI summary · NEUTRAL
· Dr Reddy's Laboratories has launched its generic Semaglutide injection in Canada. · Canada is the first G7 nation to approve this medication. · The launch follows a recent introduction in India. VERIFIED ET Stocks · 148d ★ ON YOUR LIST ☆
Margin revival, Semaglutide launch to drive Dr Reddy’s growth momentum in FY27 AI summary · POSITIVE
· Dr Reddy's Laboratories expects a gradual recovery this fiscal year, following a profit drop last year due to US business pressures. · Operations in India, Europe, and emerging markets are demonstrating healthy growth. · New product launches, including Semaglutide and Abatacept, are projected to fuel future expansion, with anticipated margin improvements from a better product mix and cost controls. VERIFIED Mint Markets · 148d ★ ON YOUR LIST ☆
Dr Reddy's Laboratories shares volatile after an 86% YoY decline in Q4 profit. Should you buy? AI summary · NEGATIVE
· Dr Reddy's Laboratories reported an 86% year-on-year decline in Q4 profit. · The company's shares experienced volatility on Wednesday, 13 May. · During the session, shares rose nearly 3% before plunging 4%.